Title |
Structure and Dynamic Regulation of Abl Kinases*
|
---|---|
Published in |
Journal of Biological Chemistry, January 2013
|
DOI | 10.1074/jbc.r112.438382 |
Pubmed ID | |
Authors |
Shoghag Panjarian, Roxana E. Iacob, Shugui Chen, John R. Engen, Thomas E. Smithgall |
Abstract |
The c-abl proto-oncogene encodes a unique protein-tyrosine kinase (Abl) distinct from c-Src, c-Fes, and other cytoplasmic tyrosine kinases. In normal cells, Abl plays prominent roles in cellular responses to genotoxic stress as well as in the regulation of the actin cytoskeleton. Abl is also well known in the context of Bcr-Abl, the oncogenic fusion protein characteristic of chronic myelogenous leukemia. Selective inhibitors of Bcr-Abl, of which imatinib is the prototype, have had a tremendous impact on clinical outcomes in chronic myelogenous leukemia and revolutionized the field of targeted cancer therapy. In this minireview, we focus on the structural organization and dynamics of Abl kinases and how these features influence inhibitor sensitivity. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 2 | 67% |
Members of the public | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 2 | <1% |
Switzerland | 1 | <1% |
France | 1 | <1% |
United Kingdom | 1 | <1% |
Canada | 1 | <1% |
Mexico | 1 | <1% |
United States | 1 | <1% |
Unknown | 213 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 38 | 17% |
Student > Master | 34 | 15% |
Student > Bachelor | 34 | 15% |
Researcher | 28 | 13% |
Student > Doctoral Student | 13 | 6% |
Other | 33 | 15% |
Unknown | 41 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 54 | 24% |
Biochemistry, Genetics and Molecular Biology | 46 | 21% |
Chemistry | 33 | 15% |
Medicine and Dentistry | 12 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
Other | 18 | 8% |
Unknown | 48 | 22% |